Er-Kim Announces Exclusive Distribution Agreement With Ascendis Pharma A/S To Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe And Turkey
Portfolio Pulse from Benzinga Newsdesk
Er-Kim has entered into an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ:ASND) to commercialize three endocrinology disease treatments in Central & Eastern Europe and Turkey. The treatments include SKYTROFA for growth hormone deficiency, YORVIPATH for chronic hypoparathyroidism, and TransCon CNP for achondroplasia. Ascendis Pharma aims to broaden patient access to these treatments in collaboration with Er-Kim, which has expertise in rare diseases and endocrinology in the region.
January 09, 2024 | 3:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ascendis Pharma A/S has signed an exclusive agreement with Er-Kim to distribute three endocrinology treatments in multiple European countries and Turkey, potentially expanding the market and patient access for its products.
The exclusive distribution agreement with Er-Kim is likely to have a positive short-term impact on Ascendis Pharma's stock price as it opens up new markets for its endocrinology treatments, which could lead to increased sales and revenue. The focus on rare diseases and the mention of successful Phase 2 trial results for one of the products may also be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80